Literature DB >> 30784093

The Dexcom glucose monitoring system-An isobornyl acrylate-free alternative for diabetic patients.

Eva Oppel1, Stefanie Kamann2, Franz-Xaver Reichl3,4, Christof Högg3,4.   

Abstract

BACKGROUND: Glucose monitoring systems, for example, Freestyle Libre (Abott) and Dexcom (Nintamed), are increasingly being used instead of conventional blood sugar measurement. However, many patients have experienced adverse skin reactions such as severe allergic contact dermatitis (ACD). Finally, in August 2017, the culprit allergen in Freestyle Libre, isobornyl acrylate (IBOA), was identified.
OBJECTIVES: After patients have developed ACD, it is recommended that they no longer use their glucose monitoring systems. Thus, it is important to find an alternative IBOA-free device. PATIENTS AND METHODS: Five patients presented with ACD caused by Freestyle Libre. Each was patch tested with allergens from the baseline series and from a plastics and glues series, and additionally with IBOA 0.1% pet. Gas chromatography-mass spectrometry (GC/MS) of the Freestyle Libre sensor and the Dexcom sensor was performed. The Dexcom sensor remained on the skin of all patients for at least 2 days.
RESULTS: All patients were sensitized to IBOA. GC/MS showed the presence of IBOA in the Freestyle Libre sensor, whereas the Dexcom sensor was IBOA-free. None of the patients had skin reactions to the Dexcom sensor.
CONCLUSIONS: Patients with Freestyle Libre and IBOA allergy may use the Dexcom sensor as an alternative for glucose monitoring.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Dexcom; Freestyle Libre; acrylates; allergic contact dermatitis; continuous glucose monitoring systems; flash glucose monitoring system; insulin pump; isobornyl acrylate; patch test

Mesh:

Substances:

Year:  2019        PMID: 30784093     DOI: 10.1111/cod.13248

Source DB:  PubMed          Journal:  Contact Dermatitis        ISSN: 0105-1873            Impact factor:   6.600


  6 in total

1.  Cutaneous Reactions to Continuous Glucose Monitoring and Continuous Subcutaneous Insulin Infusion Devices in Type 1 Diabetes Mellitus.

Authors:  Rachel S Rigo; Laura E Levin; Donald V Belsito; Maria C Garzon; Rachelle Gandica; Kristen M Williams
Journal:  J Diabetes Sci Technol       Date:  2020-05-09

2.  Effects of unrestricted access to flash glucose monitoring in type 1 diabetes.

Authors:  Klavs Würgler Hansen
Journal:  Endocrinol Diabetes Metab       Date:  2020-03-19

Review 3.  Impact of trends in new and emerging contact allergens.

Authors:  Olaf Rodriguez; Bruce A Brod; William D James
Journal:  Int J Womens Dermatol       Date:  2022-03-25

4.  Implementation of Continuous Glucose Monitoring in the Hospital: Emergent Considerations for Remote Glucose Monitoring During the COVID-19 Pandemic.

Authors:  Rodolfo J Galindo; Grazia Aleppo; David C Klonoff; Elias K Spanakis; Shivani Agarwal; Priya Vellanki; Darin E Olson; Guillermo E Umpierrez; Georgia M Davis; Francisco J Pasquel
Journal:  J Diabetes Sci Technol       Date:  2020-06-14

Review 5.  Contact Allergy-Emerging Allergens and Public Health Impact.

Authors:  Wolfgang Uter; Thomas Werfel; Jean-Pierre Lepoittevin; Ian R White
Journal:  Int J Environ Res Public Health       Date:  2020-04-01       Impact factor: 3.390

6.  Acceptability of the FreeStyle Libre Flash Glucose Monitoring System: The Experience of Young Patients With Type 1 Diabetes.

Authors:  Ayman A Al Hayek; Asirvatham A Robert; Mohamed A Al Dawish
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2020-03-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.